Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.7 USD | -3.41% |
|
-15.42% | -8.11% |
07/06 | Chardan Research Initiates Cognition Therapeutics With Buy Rating, $11 Price Target | MT |
29/05 | HC Wainwright Starts Cognition Therapeutics With Buy Rating, $10 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.11% | 6.81Cr | |
+16.49% | 12TCr | |
+21.73% | 12TCr | |
+20.87% | 2.66TCr | |
-21.81% | 1.99TCr | |
-16.89% | 1.63TCr | |
-44.74% | 1.55TCr | |
-18.81% | 1.55TCr | |
+62.72% | 1.48TCr | |
+3.09% | 1.37TCr |
- Stock Market
- Equities
- CGTX Stock
- News Cognition Therapeutics, Inc.
- Cognition Therapeutics Says Phase 2 Study of CT1812 Showed 'Positive Effects' in Alzheimer's Disease Patients